Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Hyperimmune Globulins Market Research Report 2025

Global Hyperimmune Globulins Market Research Report 2025

Industry: Pharma & Healthcare

Published Date: 2025-01-16

Pages: 97 Pages

Report ld: 3471146

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Hyperimmune Globulins Market Size(US$)

CAGR 2025-2031

Market Size,2031

USD 3,089

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 2,058 million

Market Forecast in 2031(Value)

US$ 3,089 million

CAGR

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Hyperimmune Globulins was valued at US$ 1936 million in the year 2024 and is projected to reach a revised size of US$ 3089 million by 2031, growing at a CAGR of 7.0% during the forecast period.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%. Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent. In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

The hyperimmune globulin market is primarily driven by the increasing prevalence of infectious diseases and the rising demand for immunoglobulin therapies. These therapies are crucial in treating immunodeficiency disorders and providing passive immunity against various pathogens, which fuels market growth. Additionally, advancements in plasma-derived therapies and increasing government initiatives for immunization programs contribute to market expansion.

However, the market faces significant challenges, such as the high cost of treatment and limited availability of plasma, which is a critical raw material for hyperimmune globulin production. Moreover, stringent regulatory requirements for product approval and potential side effects associated with immunoglobulin therapies can hinder market growth.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.

The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hyperimmune Globulins manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Segment by Type

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Herpes Zoster Immune Globulin

Other

Segment by Application

Government Institutions

Private Sector

Other

Consumption by Region

North America

U.S.

Canada

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Europe

Germany

France

U.K.

Italy

Russia

Latin America

Mexico

Brazil

Argentina

Middle East and Africa

Turkey

Saudi Arabia

U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Hyperimmune Globulins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Hyperimmune Globulins Market Overview

1.1 Product Definition

1.2 Hyperimmune Globulins by Type

1.2.1 Global Hyperimmune Globulins Market Value Comparison by Type (2024 VS 2031)

1.2.2 Hepatitis B Immunoglobulins

1.2.3 Rabies Immunoglobulins

1.2.4 Tetanus Immunoglobulins

1.2.5 Rho(D) Immunoglobulins

1.2.6 Herpes Zoster Immune Globulin

1.2.7 Other

1.3 Hyperimmune Globulins by Application

1.3.1 Global Hyperimmune Globulins Market Value by Application (2024 VS 2031)

1.3.2 Government Institutions

1.3.3 Private Sector

1.3.4 Other

1.4 Global Hyperimmune Globulins Market Size Estimates and Forecasts

1.4.1 Global Hyperimmune Globulins Revenue 2020-2031

1.4.2 Global Hyperimmune Globulins Sales 2020-2031

1.4.3 Global Hyperimmune Globulins Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Hyperimmune Globulins Market Competition by Manufacturers

2.1 Global Hyperimmune Globulins Sales Market Share by Manufacturers (2020-2025)

2.2 Global Hyperimmune Globulins Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Hyperimmune Globulins Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Hyperimmune Globulins, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Hyperimmune Globulins, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Hyperimmune Globulins, Product Type & Application

2.7 Global Key Manufacturers of Hyperimmune Globulins, Date of Enter into This Industry

2.8 Global Hyperimmune Globulins Market Competitive Situation and Trends

2.8.1 Global Hyperimmune Globulins Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Hyperimmune Globulins Players Market Share by Revenue

2.8.3 Global Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Hyperimmune Globulins Market Scenario by Region

3.1 Global Hyperimmune Globulins Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Hyperimmune Globulins Sales by Region: 2020-2031

3.2.1 Global Hyperimmune Globulins Sales by Region: 2020-2025

3.2.2 Global Hyperimmune Globulins Sales by Region: 2026-2031

3.3 Global Hyperimmune Globulins Revenue by Region: 2020-2031

3.3.1 Global Hyperimmune Globulins Revenue by Region: 2020-2025

3.3.2 Global Hyperimmune Globulins Revenue by Region: 2026-2031

3.4 North America Hyperimmune Globulins Market Facts & Figures by Country

3.4.1 North America Hyperimmune Globulins Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Hyperimmune Globulins Sales by Country (2020-2031)

3.4.3 North America Hyperimmune Globulins Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Hyperimmune Globulins Market Facts & Figures by Country

3.5.1 Europe Hyperimmune Globulins Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Hyperimmune Globulins Sales by Country (2020-2031)

3.5.3 Europe Hyperimmune Globulins Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Hyperimmune Globulins Market Facts & Figures by Region

3.6.1 Asia Pacific Hyperimmune Globulins Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Hyperimmune Globulins Sales by Region (2020-2031)

3.6.3 Asia Pacific Hyperimmune Globulins Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Hyperimmune Globulins Market Facts & Figures by Country

3.7.1 Latin America Hyperimmune Globulins Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Hyperimmune Globulins Sales by Country (2020-2031)

3.7.3 Latin America Hyperimmune Globulins Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country

3.8.1 Middle East and Africa Hyperimmune Globulins Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2031)

3.8.3 Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Hyperimmune Globulins Sales by Type (2020-2031)

4.1.1 Global Hyperimmune Globulins Sales by Type (2020-2025)

4.1.2 Global Hyperimmune Globulins Sales by Type (2026-2031)

4.1.3 Global Hyperimmune Globulins Sales Market Share by Type (2020-2031)

4.2 Global Hyperimmune Globulins Revenue by Type (2020-2031)

4.2.1 Global Hyperimmune Globulins Revenue by Type (2020-2025)

4.2.2 Global Hyperimmune Globulins Revenue by Type (2026-2031)

4.2.3 Global Hyperimmune Globulins Revenue Market Share by Type (2020-2031)

4.3 Global Hyperimmune Globulins Price by Type (2020-2031)

5 Segment by Application

5.1 Global Hyperimmune Globulins Sales by Application (2020-2031)

5.1.1 Global Hyperimmune Globulins Sales by Application (2020-2025)

5.1.2 Global Hyperimmune Globulins Sales by Application (2026-2031)

5.1.3 Global Hyperimmune Globulins Sales Market Share by Application (2020-2031)

5.2 Global Hyperimmune Globulins Revenue by Application (2020-2031)

5.2.1 Global Hyperimmune Globulins Revenue by Application (2020-2025)

5.2.2 Global Hyperimmune Globulins Revenue by Application (2026-2031)

5.2.3 Global Hyperimmune Globulins Revenue Market Share by Application (2020-2031)

5.3 Global Hyperimmune Globulins Price by Application (2020-2031)

6 Key Companies Profiled

6.1 CSL Behring

6.1.1 CSL Behring Company Information

6.1.2 CSL Behring Description and Business Overview

6.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.1.4 CSL Behring Hyperimmune Globulins Product Portfolio

6.1.5 CSL Behring Recent Developments/Updates

6.2 Grifols

6.2.1 Grifols Company Information

6.2.2 Grifols Description and Business Overview

6.2.3 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Grifols Hyperimmune Globulins Product Portfolio

6.2.5 Grifols Recent Developments/Updates

6.3 Biotest

6.3.1 Biotest Company Information

6.3.2 Biotest Description and Business Overview

6.3.3 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Biotest Hyperimmune Globulins Product Portfolio

6.3.5 Biotest Recent Developments/Updates

6.4 Kedrion

6.4.1 Kedrion Company Information

6.4.2 Kedrion Description and Business Overview

6.4.3 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Kedrion Hyperimmune Globulins Product Portfolio

6.4.5 Kedrion Recent Developments/Updates

6.5 CBPO

6.5.1 CBPO Company Information

6.5.2 CBPO Description and Business Overview

6.5.3 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.5.4 CBPO Hyperimmune Globulins Product Portfolio

6.5.5 CBPO Recent Developments/Updates

6.6 Emergent (Cangene)

6.6.1 Emergent (Cangene) Company Information

6.6.2 Emergent (Cangene) Description and Business Overview

6.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio

6.6.5 Emergent (Cangene) Recent Developments/Updates

6.7 Kamada

6.7.1 Kamada Company Information

6.7.2 Kamada Description and Business Overview

6.7.3 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Kamada Hyperimmune Globulins Product Portfolio

6.7.5 Kamada Recent Developments/Updates

6.8 CNBG

6.8.1 CNBG Company Information

6.8.2 CNBG Description and Business Overview

6.8.3 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.8.4 CNBG Hyperimmune Globulins Product Portfolio

6.8.5 CNBG Recent Developments/Updates

6.9 Hualan Bio

6.9.1 Hualan Bio Company Information

6.9.2 Hualan Bio Description and Business Overview

6.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio

6.9.5 Hualan Bio Recent Developments/Updates

6.10 Shanghai RAAS

6.10.1 Shanghai RAAS Company Information

6.10.2 Shanghai RAAS Description and Business Overview

6.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio

6.10.5 Shanghai RAAS Recent Developments/Updates

6.11 Sichuan Yuanda Shuyang

6.11.1 Sichuan Yuanda Shuyang Company Information

6.11.2 Sichuan Yuanda Shuyang Description and Business Overview

6.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio

6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates

6.12 ADMA Biologics

6.12.1 ADMA Biologics Company Information

6.12.2 ADMA Biologics Description and Business Overview

6.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)

6.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio

6.12.5 ADMA Biologics Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Hyperimmune Globulins Industry Chain Analysis

7.2 Hyperimmune Globulins Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Hyperimmune Globulins Production Mode & Process Analysis

7.4 Hyperimmune Globulins Sales and Marketing

7.4.1 Hyperimmune Globulins Sales Channels

7.4.2 Hyperimmune Globulins Distributors

7.5 Hyperimmune Globulins Customer Analysis

8 Hyperimmune Globulins Market Dynamics

8.1 Hyperimmune Globulins Industry Trends

8.2 Hyperimmune Globulins Market Drivers

8.3 Hyperimmune Globulins Market Challenges

8.4 Hyperimmune Globulins Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Hyperimmune Globulins Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Hyperimmune Globulins Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Hyperimmune Globulins Market Competitive Situation by Manufacturers in 2024

Table 4. Global Hyperimmune Globulins Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Hyperimmune Globulins Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Hyperimmune Globulins Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Hyperimmune Globulins Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Hyperimmune Globulins Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Hyperimmune Globulins, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Hyperimmune Globulins, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Hyperimmune Globulins, Product Type & Application

Table 12. Global Key Manufacturers of Hyperimmune Globulins, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Hyperimmune Globulins by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperimmune Globulins as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)

Table 18. Global Hyperimmune Globulins Sales Market Share by Region (2020-2025)

Table 19. Global Hyperimmune Globulins Sales by Region (2026-2031) & (K Units)

Table 20. Global Hyperimmune Globulins Sales Market Share by Region (2026-2031)

Table 21. Global Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Hyperimmune Globulins Revenue Market Share by Region (2020-2025)

Table 23. Global Hyperimmune Globulins Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Hyperimmune Globulins Revenue Market Share by Region (2026-2031)

Table 25. North America Hyperimmune Globulins Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 27. North America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 28. North America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Hyperimmune Globulins Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 32. Europe Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 33. Europe Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Hyperimmune Globulins Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Hyperimmune Globulins Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Hyperimmune Globulins Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Hyperimmune Globulins Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Hyperimmune Globulins Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Hyperimmune Globulins Sales (K Units) by Type (2020-2025)

Table 51. Global Hyperimmune Globulins Sales (K Units) by Type (2026-2031)

Table 52. Global Hyperimmune Globulins Sales Market Share by Type (2020-2025)

Table 53. Global Hyperimmune Globulins Sales Market Share by Type (2026-2031)

Table 54. Global Hyperimmune Globulins Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Hyperimmune Globulins Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Hyperimmune Globulins Revenue Market Share by Type (2020-2025)

Table 57. Global Hyperimmune Globulins Revenue Market Share by Type (2026-2031)

Table 58. Global Hyperimmune Globulins Price (USD/Unit) by Type (2020-2025)

Table 59. Global Hyperimmune Globulins Price (USD/Unit) by Type (2026-2031)

Table 60. Global Hyperimmune Globulins Sales (K Units) by Application (2020-2025)

Table 61. Global Hyperimmune Globulins Sales (K Units) by Application (2026-2031)

Table 62. Global Hyperimmune Globulins Sales Market Share by Application (2020-2025)

Table 63. Global Hyperimmune Globulins Sales Market Share by Application (2026-2031)

Table 64. Global Hyperimmune Globulins Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Hyperimmune Globulins Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Hyperimmune Globulins Revenue Market Share by Application (2020-2025)

Table 67. Global Hyperimmune Globulins Revenue Market Share by Application (2026-2031)

Table 68. Global Hyperimmune Globulins Price (USD/Unit) by Application (2020-2025)

Table 69. Global Hyperimmune Globulins Price (USD/Unit) by Application (2026-2031)

Table 70. CSL Behring Company Information

Table 71. CSL Behring Description and Business Overview

Table 72. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. CSL Behring Hyperimmune Globulins Product

Table 74. CSL Behring Recent Developments/Updates

Table 75. Grifols Company Information

Table 76. Grifols Description and Business Overview

Table 77. Grifols Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Grifols Hyperimmune Globulins Product

Table 79. Grifols Recent Developments/Updates

Table 80. Biotest Company Information

Table 81. Biotest Description and Business Overview

Table 82. Biotest Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Biotest Hyperimmune Globulins Product

Table 84. Biotest Recent Developments/Updates

Table 85. Kedrion Company Information

Table 86. Kedrion Description and Business Overview

Table 87. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Kedrion Hyperimmune Globulins Product

Table 89. Kedrion Recent Developments/Updates

Table 90. CBPO Company Information

Table 91. CBPO Description and Business Overview

Table 92. CBPO Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. CBPO Hyperimmune Globulins Product

Table 94. CBPO Recent Developments/Updates

Table 95. Emergent (Cangene) Company Information

Table 96. Emergent (Cangene) Description and Business Overview

Table 97. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Emergent (Cangene) Hyperimmune Globulins Product

Table 99. Emergent (Cangene) Recent Developments/Updates

Table 100. Kamada Company Information

Table 101. Kamada Description and Business Overview

Table 102. Kamada Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Kamada Hyperimmune Globulins Product

Table 104. Kamada Recent Developments/Updates

Table 105. CNBG Company Information

Table 106. CNBG Description and Business Overview

Table 107. CNBG Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. CNBG Hyperimmune Globulins Product

Table 109. CNBG Recent Developments/Updates

Table 110. Hualan Bio Company Information

Table 111. Hualan Bio Description and Business Overview

Table 112. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Hualan Bio Hyperimmune Globulins Product

Table 114. Hualan Bio Recent Developments/Updates

Table 115. Shanghai RAAS Company Information

Table 116. Shanghai RAAS Description and Business Overview

Table 117. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Shanghai RAAS Hyperimmune Globulins Product

Table 119. Shanghai RAAS Recent Developments/Updates

Table 120. Sichuan Yuanda Shuyang Company Information

Table 121. Sichuan Yuanda Shuyang Description and Business Overview

Table 122. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 123. Sichuan Yuanda Shuyang Hyperimmune Globulins Product

Table 124. Sichuan Yuanda Shuyang Recent Developments/Updates

Table 125. ADMA Biologics Company Information

Table 126. ADMA Biologics Description and Business Overview

Table 127. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 128. ADMA Biologics Hyperimmune Globulins Product

Table 129. ADMA Biologics Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Hyperimmune Globulins Distributors List

Table 133. Hyperimmune Globulins Customers List

Table 134. Hyperimmune Globulins Market Trends

Table 135. Hyperimmune Globulins Market Drivers

Table 136. Hyperimmune Globulins Market Challenges

Table 137. Hyperimmune Globulins Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

Table 141. Authors List of This Report

List of Figures

Figure 1. Product Picture of Hyperimmune Globulins

Figure 2. Global Hyperimmune Globulins Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hyperimmune Globulins Market Share by Type: 2024 & 2031

Figure 4. Hepatitis B Immunoglobulins Product Picture

Figure 5. Rabies Immunoglobulins Product Picture

Figure 6. Tetanus Immunoglobulins Product Picture

Figure 7. Rho(D) Immunoglobulins Product Picture

Figure 8. Herpes Zoster Immune Globulin Product Picture

Figure 9. Other Product Picture

Figure 10. Global Hyperimmune Globulins Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Hyperimmune Globulins Market Share by Application: 2024 & 2031

Figure 12. Government Institutions

Figure 13. Private Sector

Figure 14. Other

Figure 15. Global Hyperimmune Globulins Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Hyperimmune Globulins Market Size (2020-2031) & (US$ Million)

Figure 17. Global Hyperimmune Globulins Sales (2020-2031) & (K Units)

Figure 18. Global Hyperimmune Globulins Average Price (USD/Unit) & (2020-2031)

Figure 19. Hyperimmune Globulins Report Years Considered

Figure 20. Hyperimmune Globulins Sales Share by Manufacturers in 2024

Figure 21. Global Hyperimmune Globulins Revenue Share by Manufacturers in 2024

Figure 22. Global 5 and 10 Largest Hyperimmune Globulins Players: Market Share by Revenue in Hyperimmune Globulins in 2024

Figure 23. Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 24. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 25. North America Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 26. North America Hyperimmune Globulins Revenue Market Share by Country (2020-2031)

Figure 27. U.S. Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Canada Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Europe Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 30. Europe Hyperimmune Globulins Revenue Market Share by Country (2020-2031)

Figure 31. Germany Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. France Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. U.K. Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Italy Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Russia Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Asia Pacific Hyperimmune Globulins Sales Market Share by Region (2020-2031)

Figure 37. Asia Pacific Hyperimmune Globulins Revenue Market Share by Region (2020-2031)

Figure 38. China Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Japan Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. South Korea Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. India Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Australia Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. China Taiwan Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Indonesia Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Thailand Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Malaysia Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Philippines Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Latin America Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 49. Latin America Hyperimmune Globulins Revenue Market Share by Country (2020-2031)

Figure 50. Mexico Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Brazil Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Argentina Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2020-2031)

Figure 54. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2020-2031)

Figure 55. Turkey Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Saudi Arabia Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. U.A.E Hyperimmune Globulins Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Global Sales Market Share of Hyperimmune Globulins by Type (2020-2031)

Figure 59. Global Revenue Market Share of Hyperimmune Globulins by Type (2020-2031)

Figure 60. Global Hyperimmune Globulins Price (USD/Unit) by Type (2020-2031)

Figure 61. Global Sales Market Share of Hyperimmune Globulins by Application (2020-2031)

Figure 62. Global Revenue Market Share of Hyperimmune Globulins by Application (2020-2031)

Figure 63. Global Hyperimmune Globulins Price (USD/Unit) by Application (2020-2031)

Figure 64. Hyperimmune Globulins Value Chain

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Hyperimmune Globulins market size from 2025 to 2031? zhanKai

The annual compound growth rate of the global Hyperimmune Globulins market is 7% 2025 to 2031.

What was the global market size of Hyperimmune Globulins in 2031? shouQi

What was the global market size of Hyperimmune Globulins in 2025? shouQi

Which companies rank high in the global Hyperimmune Globulins market? shouQi

Which region is expected to have the highest market share? shouQi

Related Reports

Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Hyperimmune Globulins market size was US$ 2058 million in 2025 and is forecast to reach a readjusted size of US$ 3284 million by 2032 with a CAGR of 7.0% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 91
USD 4250.00
(Single User License)
Global Hyperimmune Globulins Market Research Report 2026
The global Hyperimmune Globulins market was valued at US$ 2058 million in 2025 and is anticipated to reach US$ 3284 million by 2032, at a CAGR of 7.0% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 119
USD 2900.00
(Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Hyperimmune Globulins was estimated to be worth US$ 2058 million in 2025 and is projected to reach US$ 3284 million, growing at a CAGR of 7.0% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 115
USD 3950.00
(Single User License)
Global Hyperimmune Globulins Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Hyperimmune Globulins market is projected to grow from US$ 1936 million in 2024 to US$ 3089 million by 2031, at a CAGR of 7.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 164
USD 4900.00
(Single User License)
Global Hyperimmune Globulins Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Hyperimmune Globulins was estimated to be worth US$ 1936 million and is forecast to reach approximately US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 141
USD 5900.00
(Single User License)
Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Hyperimmune Globulins market size was US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 95
USD 4250.00
(Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Hyperimmune Globulins was estimated to be worth US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 113
USD 3950.00
(Single User License)
Global and Japan Hyperimmune Globulins Market Report & Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published Date: 2024-09-05
Pages: 128
USD 4350.00
(Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published Date: 2024-09-05
Pages: 129
USD 3950.00
(Single User License)
Global Hyperimmune Globulins Market Insights, Forecast to 2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published Date: 2024-09-05
Pages: 160
USD 4900.00
(Single User License)

Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Hyperimmune Globulins market size was US$ 2058 million in 2025 and is forecast to reach a readjusted size of US$ 3284 million by 2032 with a CAGR of 7.0% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 91
USD 4250.00 (Single User License)
Global Hyperimmune Globulins Market Research Report 2026
The global Hyperimmune Globulins market was valued at US$ 2058 million in 2025 and is anticipated to reach US$ 3284 million by 2032, at a CAGR of 7.0% from 2026 to 2032.
Published: 2026-01-04
Pages: 119
USD 2900.00 (Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Hyperimmune Globulins was estimated to be worth US$ 2058 million in 2025 and is projected to reach US$ 3284 million, growing at a CAGR of 7.0% from 2026 to 2032.
Published: 2026-01-04
Pages: 115
USD 3950.00 (Single User License)
Global Hyperimmune Globulins Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Hyperimmune Globulins market is projected to grow from US$ 1936 million in 2024 to US$ 3089 million by 2031, at a CAGR of 7.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 164
USD 4900.00 (Single User License)
Global Hyperimmune Globulins Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Hyperimmune Globulins was estimated to be worth US$ 1936 million and is forecast to reach approximately US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 141
USD 5900.00 (Single User License)
Global Hyperimmune Globulins Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Hyperimmune Globulins market size was US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 95
USD 4250.00 (Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Hyperimmune Globulins was estimated to be worth US$ 1936 million in 2024 and is forecast to a readjusted size of US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 113
USD 3950.00 (Single User License)
Global and Japan Hyperimmune Globulins Market Report & Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published: 2024-09-05
Pages: 128
USD 4350.00 (Single User License)
Hyperimmune Globulins- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published: 2024-09-05
Pages: 129
USD 3950.00 (Single User License)
Global Hyperimmune Globulins Market Insights, Forecast to 2030
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Published: 2024-09-05
Pages: 160
USD 4900.00 (Single User License)